References
- Deterding, R. R., LaVange, L. M., Engels, J. M., Mathews, D. W., Coquillette, S. J., Brody, A. S., Millard, S. P., Ramsey, B. W., and Cystic Fibrosis Therapeutics Development Network and the Inspire 08-103 Working Group* (2007), “Phase 2 Randomized Safety and Efficacy Trial of Nebulized Denufosol Tetrasodium in Cystic Fibrosis,” American Journal of Respiratory and Critical Care Medicine, 176, 362–369. DOI: https://doi.org/10.1164/rccm.200608-1238OC.
- Gelman, D. (1988), “Treating War’s Psychic Wounds,” Amstat News, 62–69.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2017), ICH Harmonized Guideline E9 (R1) Estimands and Sensitivity analysis in Clinical Trials, Brussels, Belgium: ICH, available at https://www.ema.europa.eu/documents/scientific-guideline/draft-ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical_en.pdf.
- Kulka, R. A., Schlenger, W. E., Fairbank, J. A., Hough, R. L., Jordan, B. K., Marmar, C. R., and Weiss, D. S. (1990), Trauma and the Vietnam War Generation: Report of Findings From the National Vietnam Veterans Readjustment Study, Brussels, Belgium: Brunner/Mazel Psychological Stess Series.
- LaVange, L. M. (2013), “The Role of Statistics in Regulatory Decision Making,” Therapeutic Innovation & Regulatory Science, 48, 12–19. DOI: https://doi.org/10.1177/2168479013514418.
- LaVange, L. M. (2019), “Statistics at the FDA: Reflections on the Past Six Years,” Statistics in Biopharmaceutical Research, 11, 1–12, DOI: https://doi.org/10.1080/19466315.2019.1571322.
- Lavange, L. M., Kalsbeek, W. D., Sorlie, P. D., Avilés-Santa, L. M., Kaplan, R. C., Barnhart, J., Liu, K., Giachello, A., Lee, D. J., Ryan, J., Criqui, M. H., and Elder, J. P. (2010), “Sample Design and Cohort Selection in the Hispanic Community Health Study/Study of Latinos,” Annals of Epidemiology, 20, 642–649. DOI: https://doi.org/10.1016/j.annepidem.2010.05.006.
- LaVange, L. M., and Koch, G. G. (2007). “Statistical Projection of Clinical Subsample Estimates to a Survey Population,” Journal of Periodontology, 78, 1400–1406. DOI: https://doi.org/10.1902/jop.2007.070110.
- LaVange, L. M., and Permutt, T. (2016), “A Regulatory Perspective on Missing Data in the Aftermath of the NRC Report,” Statistics in Medicine, 35, 2853–2864. DOI: https://doi.org/10.1002/sim.6840.
- Nussbaum, B. D. (2018), “Statistics: Essential Now More Than Ever,” Journal of the American Statistical Association, 113, 489–493, DOI: https://doi.org/10.1080/01621459.2018.1463486.
- Permutt, T. (2016), “A Taxonomy of Estimands for Regulatory Clinical Trials With Discontinuations,” Statistics in Medicine, 35, 2865–2875. DOI: https://doi.org/10.1002/sim.6841.
- Wasserstein, R. L., and Lazar, N. A. (2016), “The ASA’s Statement on p-Values: Context, Process, and Purpose,” The American Statistician, 70, 129–133, DOI: https://doi.org/10.1080/00031305.2016.1154108.
- Woodcock, J., and LaVange, L. M. (2017), “Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both,” New England Journal of Medicine, 377, 62–70, DOI: https://doi.org/10.1056/NEJMra1510062.